COMPANY

Migra-Therapeutics

HQ: Atlanta, GA source · migratherapeutics.com ↗ · Southeast

Keywords: nanoparticles oncology

Location: Atlanta, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

NIH awards 6

Annual award amounts. Total $2.6M.

Sep 14, 2026 NIH award 1R43CA310425-01A1 FY2026: $314,896 awarded for that fiscal year; activity R43 (SBIR); PI ZHU, LEI; recipient as written: MIGRA-THERAPEUTICS, LLC, Atlanta, GA. Development of tumor targeting and stroma penet source ↗
Jul 20, 2023 NIH award 5R44CA246827-03 FY2023: $841,919 awarded for that fiscal year; activity R44 (SBIR); PI ZHU, LEI; recipient as written: MIGRA-THERAPEUTICS, LLC, Atlanta, GA. Translational Development of a Targeted and Strom source ↗
Sep 15, 2022 NIH award 2R44CA246827-02 FY2022: $934,438 awarded for that fiscal year; activity R44 (SBIR); PI ZHU, LEI; recipient as written: MIGRA-THERAPEUTICS, LLC, Atlanta, GA. Translational Development of a Targeted and Strom source ↗
Sep 17, 2020 NIH award 3R41CA247165-01A1S1 FY2020: $105,503 awarded for that fiscal year; activity R41 (STTR); PI YANG, LILY; recipient as written: MIGRA-THERAPEUTICS, LLC, Atlanta, GA. Tumor Stroma Breaking System for Efficient source ↗
Jun 23, 2020 NIH award 1R41CA247165-01A1 FY2020: $224,860 awarded for that fiscal year; activity R41 (STTR); PI YANG, LILY; recipient as written: MIGRA-THERAPEUTICS, LLC, Atlanta, GA. Tumor Stroma Breaking System for Efficient De source ↗
Sep 19, 2019 NIH award 1R43CA246827-01 FY2019: $224,425 awarded for that fiscal year; activity R43 (SBIR); PI ZHU, LEI; recipient as written: MIGRA-THERAPEUTICS, LLC, Atlanta, GA. Translational Development of a Targeted and Strom source ↗

NIH award NIH awarded $315K (SBIR Phase I 1R43CA310425-01A1, new, notice Sep 14, 2026). NIH RePORTER 1R43CA310425-01A1 (Sep 14, 2026)
Evidence (1 event)
- Sep 14, 2026 · NIH RePORTER 1R43CA310425-01A1
  Organization: MIGRA-THERAPEUTICS, LLC; City/State: Atlanta, GA; Project number: 1R43CA310425-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 314896; Administering IC: National Cancer Institute; Project title: Development of tumor targeting and stroma penetrating toxin for pancreatic cancer treatment; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals